Executive Director, Clinical Biomarker Strategy & Development
Ultragenyx
Novato
Rachael E. Hawtin PhD. Is Executive Director, Clinical Biomarker Strategy at Ultragenyx, a company that is focused on therapeutic development in rare and ultra-rare genetic diseases. Ultragenyx is exploring multiple avenues to apply biomarkers to accelerate drug development and deliver therapeutics to patients in need.
Rachael has over 27 years’ experience in translational sciences and drug development, including oncology, immuno-oncology, autoimmunity, and rare diseases encompassing a range of indications and therapeutic treatment modalities. Throughout her career she has focused on improving the understanding of disease pathobiology and therapeutic mechanism-of-action, to enable rationale-based drug development, and to better pair patients with treatments. She has successfully led integrative programs that support indication selection and expansion, dose optimization, combination strategies and lifecycle management. Her leadership roles have encompassed research target selection, through to leadership of phase 2 and 3 clinical studies.
Disclosure information not submitted.
The Value And Application Of Biomarker Strategy To Rare Disease Drug Development
Monday, October 21, 2024
10:30 AM – 11:00 AM MT